Related Articles
Gastrointestinal perforation during treatment with erlotinib plus bevacizumab in two patients with non‑small cell lung cancer exhibiting epidermal growth factor receptor mutations: A case report
Synchronal pulmonary sarcomatoid carcinoma and lung adenocarcinoma EML4‑ALK fusion: A case report
Investigation of EGFR mutations in non‑small cell lung cancer usually undetectable by PCR methods
Phase II study of erlotinib for previously treated patients with EGFR wild‑type non‑small‑cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System
Integrin‑linked kinase pathway in heterogeneous pulmonary sarcomatoid carcinoma